Arkolith/Insider Trading/ETON/Form 4

Krempa David

Chief Business OfficerEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed May 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.2M
Net Open-Market Flow
-$3.2M
Transactions
15
10 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)12K$1.37$17K38K
May 27, 2026Option exercise(M)7K$3.58$26K45K
May 27, 2026Sell(S)20K$31.47$619K25K
May 26, 2026Sell(S)38K$31.49$1.2M25K
May 26, 2026Option exercise(M)25K$1.38$35K50K
May 26, 2026Option exercise(M)13K$1.37$17K63K
May 22, 2026Option exercise(M)31K$3.58$110K68K
May 22, 2026Sell(S)33K$33.22$1.1M35K
May 22, 2026Sell(S)9K$33.88$316K26K
May 22, 2026Sell(S)519$35.00$18K25K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)12K—$00
May 27, 2026Option exercise(M)7K—$0118K
May 26, 2026Option exercise(M)25K—$00
May 26, 2026Option exercise(M)13K—$012K
May 22, 2026Option exercise(M)31K—$0126K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-018628) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML